Industry News Sofinnova Partners BioPharma Dive

Sofinnova Closes €725M Crossover Fund to Bridge Europe's Late-Stage Financing Gap

  • Sofinnova Partners closed Sofinnova Crossover II at €725M (about $815M), its largest fund; the firm manages about €4B.
  • It plans around 15 investments in late-stage drug and device companies near commercialization, mostly European.
  • Partner Kinam Hong frames Europe's problem as scale-up financing, not innovation; BioPharma Dive data show over 70 private rounds this year went to Phase 1-or-later biotechs.
Points Based on public reports

The signal is crossover money returning as the IPO window reopens. A €725M fund written into roughly 15 names implies cheques large enough to carry companies to a listing or a sale, the layer European biotech has lacked. Watch whether it truly stays in Europe: US-listing pull and US-heavy co-investors often drag the best companies westward. Abivax's rise is the pitch; the test is repeating it.